Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-03-01
2011-03-01
Kosar, Andrew D (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S473000, C540S474000
Reexamination Certificate
active
07897590
ABSTRACT:
Methods to elevate progenitor and stem cell counts in animal subjects using compounds which bind to the chemokine receptor CXCR4 are disclosed. Preferred embodiments of such compounds are of the formulain-line-formulae description="In-line Formulae" end="lead"?Z-linker-Z′ (1)in-line-formulae description="In-line Formulae" end="tail"?or pharmaceutically acceptable salt thereofwherein Z is a cyclic polyamine containing 9-32 ring members of which 3-8 are nitrogen atoms, said nitrogen atoms separated from each other by at least 2 carbon atoms, and wherein said heterocycle may optionally contain additional heteroatoms besides nitrogen and/or may be fused to an additional ring system;or Z is of the formulawherein A comprises a monocyclic or bicyclic fused ring system containing at least one N and B is H or an organic moiety of 1-20 atoms,Z′ may be embodied in a form as defined by Z above, or alternatively may be of the formulain-line-formulae description="In-line Formulae" end="lead"?—N(R)—(CR2)n—Xin-line-formulae description="In-line Formulae" end="tail"?wherein each R is independently H or straight, branched or cyclic alkyl (1-6C), n is 1 or 2, and X is an aromatic ring, including heteroaromatic rings, or is a mercaptan;“linker” represents a bond, alkylene (1-6C) or may comprise aryl, fused aryl, oxygen atoms contained in an alkylene chain, or may contain keto groups or nitrogen or sulfur atoms.
REFERENCES:
patent: 5021409 (1991-06-01), Murrer et al.
patent: 5047527 (1991-09-01), Handel et al.
patent: 5374416 (1994-12-01), Rousseaux et al.
patent: 5582823 (1996-12-01), Souza
patent: 5583131 (1996-12-01), Bridger et al.
patent: 5606053 (1997-02-01), Prashad et al.
patent: 5612478 (1997-03-01), Xu et al.
patent: 5698546 (1997-12-01), Bridger et al.
patent: 5756728 (1998-05-01), Xu et al.
patent: 5801281 (1998-09-01), Xu et al.
patent: 5817807 (1998-10-01), Bridger et al.
patent: 6001826 (1999-12-01), Murrer et al.
patent: 6365583 (2002-04-01), MacFarland et al.
patent: 6667320 (2003-12-01), Bridger et al.
patent: 6670354 (2003-12-01), MacFarland et al.
patent: 6987102 (2006-01-01), Bridger et al.
patent: 7169750 (2007-01-01), Bridger et al.
patent: 2002/0058653 (2002-05-01), MacFarland et al.
patent: 2002/0156034 (2002-10-01), Tudan et al.
patent: 2003/0130250 (2003-07-01), Bridger et al.
patent: 2004/0102428 (2004-05-01), Bridger et al.
patent: 2005/0043367 (2005-02-01), Bridger et al.
patent: 2006/0193826 (2006-08-01), Bridger et al.
patent: 2006/0223180 (2006-10-01), Bridger et al.
patent: 0 296 522 (1988-12-01), None
patent: 0 434 385 (1991-06-01), None
patent: 0 305 320 (1992-09-01), None
patent: 1 016 413 (2000-07-01), None
patent: WO-91/05762 (1991-05-01), None
patent: WO-92/16494 (1992-10-01), None
patent: WO-99/50461 (1999-10-01), None
patent: WO-99/65507 (1999-12-01), None
patent: WO-00/02870 (2000-01-01), None
patent: WO-00/18885 (2000-04-01), None
patent: WO-00/28987 (2000-05-01), None
patent: WO-00/45814 (2000-08-01), None
patent: WO-00/56729 (2000-09-01), None
patent: WO-00/66112 (2000-11-01), None
patent: WO-01/44229 (2001-06-01), None
patent: WO-01/85196 (2001-11-01), None
patent: WO-01/94420 (2001-12-01), None
patent: WO-02/22599 (2002-03-01), None
patent: WO-02/22600 (2002-03-01), None
patent: WO-02/26721 (2002-04-01), None
patent: WO-02/34745 (2002-05-01), None
patent: WO-02/058653 (2002-08-01), None
patent: WO-03/011277 (2003-02-01), None
Abi-Younes et al., Circ. Res. (2000) 86:131-138.
Aiuti et al., J. Exp. Med. (1997) 185:111-120.
Bleul et al., J. Exp. Med. (1996) 184:1101-1109.
Broxmeyer et al., Blood Cells, Molecules and Diseases (1998) 24:14-30.
Broxmeyer et al., Exp. Hematol. (1995) 23:335-340.
Broxmeyer et al., Exp. Hematol. (2002) 30(6 Suppl. 1):45 (Abstract No. 34).
Burdach, Klin. Padiatr. (1991) pp. 302-310.
CAS Registry No. 155148-31-5, accessed Apr. 1, 2005, 1 page.
ChemIDplus Lite Record, JM 3100, accessed Apr. 1, 2005, 1 page.
Croop et al., Bone Marrow Transplantation(2000) 26:1271-1279.
Dale et al., Am. J. of Hematol. (1998) 57:7-15.
Database Biosis [Online], Database Accession No. PREV200250113, Conrad et al.
Database Biosis [Online], Database Accession No. PREV200261505, Broxmeyer et al.
Database CIN [Online], retrieved from STN Accession No. 31(31):31132P.
De Clercq et al., Antimicrob. Agents Chemother. (1994) 38(4):668-674.
Dijulio, Oncol. Nurs. Forum. (1991) 18(2) Suppl.:3-6.
Egger et al., Brit. J. Haem. (1998) 103:1181-1183.
Fedyk et al., J. Leukoc. Biol. (1999) 66:667-673.
Finer, Washington Post (Mar. 31, 2005), p. A2.
Gear et al., Blood (2001) 97:937-945.
Gerlach et al., J. of Biol. Chem. (2001) 276(17):14153-14160.
Glaspy et al., Blood (1997) 90:2939-2951.
Glaspy et al., Cancer Chemother. Pharmacol. (1996) 38(Suppl.):S53-S57.
Hendrix et al., Antimicrobial Agents and Chemotherapy (2000) 44(6):1667-1673.
Hodohara et al., Blood (2000) 95:769-775.
Jackson et al., J. Clin. Invest. (2001) 107:1395-1402.
Jo et al., J. Clin. Invest. (2000) 105:101-111.
King et al., Blood (2001) 97:1534-1542.
Kocher et al., Nature Med. (2001) 7:430-436.
Lord et al., Blood (1992) 79(10):2605-2609.
Ma et al., Immunity (1999) 10:463-471.
Ma et al., PNAS USA (1998) 95:9448-9453.
Maekawa et al., Internal Med. (2000) 39:90-100.
Majka et al., Blood (2000) 96:4142-4151.
Moore et al., Ann. N. Y. Acad. Sci. (2001) 938:36-45.
Nagasawa et al., Int. J. Hematol. (2000) 72:408-411.
NIAID Chemical Compound Search, 1,1′-[1,4-Phenylenebis(methylene)]bis[1,4,8,11-tetraazacyclotetradecane], accessed Apr. 1, 2005, 1 page.
Partial European Search Report for Application No. 02750370.5, date mailed on Oct. 16, 2007, 16 pages.
Peled et al., Science (1999) 283:845-848.
Ponomaryov et al., J. Clin. Invest. (2000) 106:1331-1339.
Pruijt et al., Cur. Op. In Hematol. (1999) 6:152-158.
Purves et al. (eds.), Life: The Science of Biology, Sinauer Associates, Inc. (1992) pp. 928-929.
Riviere et al., Blood (1999) 95:1511-1523.
Rosenfeld et al., Bone Marrow Transplantation (1997) 17:179-183.
Schols et al., Antiviral Res. (1997) 35:147-156.
Smits et al., J. Cell. Mol. Med. (2005) 9(1):25-36.
Szabo et al., British Journal of Pharmacology (1998) 125:379-387.
Tachibana et al., Nature (1998) 393:591-594.
Vadhan-Raj et al., Ann. Intern. Med. (1997) 126:673-681.
Van Os et al., Blood 96(11 Part 2):308b (Abstract No. 5074).
Viardot et al., Ann. Hematol. (1998) 77:194-197.
Voermans et al., Blood (2001) 97:799-804.
Witvrouw et al., Antiviral Chemistry and Chemotherapy (1996) 7(1):27-30.
Zou et al., Nature (1998) 393:595-599.
Kawabata et al., PNAS USA (1999) 96(10):5663-5667.
Notice of Reasons for Rejection for Japanese Patent Application No. 2003-516507, mailed on Oct. 16, 2008, 5 pages.
Shen et al., J Immunol (2001) 166(8):5027-5033.
Supplementary European Search Report for EP 04753722.0, mailed Feb. 26, 2008, 5 pages.
U.S. Appl. No. 10/209,001, filed Jul. 30, 2002.
Preliminary Amendment for U.S. Appl. No. 10/209,001, filed Nov. 7, 2002.
Restriction Requirement for U.S. Appl. No. 10/209,001, mailed Sep. 21, 2004.
Response to Restriction Requirement and Amendment for U.S. Appl. No. 10/209,001, filed Oct. 14, 2004.
Restriction Requirement for U.S. Appl. No. 10/209,001, mailed on Dec. 28, 2004.
Response for U.S. Appl. No. 10/209,001, filed Jan. 7, 2005.
Non-Final Office Action for U.S. Appl. No. 10/209,001, mailed Apr. 6, 2005.
Amendment for U.S. Appl. No. 10/209,001, filed May 31, 2005.
Interview Summary for U.S. Appl. No. 10/209,001, mailed Jun. 10, 2005.
Notice of Allowance for 10/209,001, mailed on Jul. 13, 2005.
Application for Patent Term Adjustment for U.S. Appl. No. 10/209,001, filed Feb. 17, 2006.
Decision for Request for Reconsideration of Patent Term Adjustment for U.S. Appl. No. 10/209,001, mailed Oct. 2, 2006.
U.S. Appl. No. 10/456,942, filed Jun. 5, 2003.
Restriction Requirement for 10/456,942, mailed on Dec. 13, 2005.
Amendment/Restriction Requirement for U.S. Appl. No. 10/456,942, filed Jan. 12, 2006.
Non-Final Office Action for U.S. Appl. No. 10/456,942, mailed Mar. 13, 2006.
Amendment for U.S. Appl. No. 10/456,942, filed Jul.
Abrams Michael J.
Bridger Gary J.
Broxmeyer Hal E.
Calandra Gary B.
Dale David C.
Genzyme Corporation
Kosar Andrew D
Morrison & Foerster / LLP
LandOfFree
Methods to mobilize progenitor/stem cells does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods to mobilize progenitor/stem cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods to mobilize progenitor/stem cells will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2655481